Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05343143 · ClinicalTrials.gov registry record · NA
NeuraGen 3D Pilot Study
A NA study, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT05343143 is a NA study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 1 participants.
The verdict
NCT05343143, a NA study, was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.
Interventions
- DEVICE NeuraGen 3D Nerve Guide Matrix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2022-05-15 |
| Est. Completion | 2024-05-13 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05343143
The ClinicalTrials.gov registry entry for NCT05343143 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NeuraGen 3D Nerve Guide Matrix is the first listed.
NCT05343143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05343143 about?
NCT05343143 is a clinical study titled "NeuraGen 3D Pilot Study". This is a 10-subject, 12-month follow-up, prospective, multi-center, open-label, single arm clinical trial designed to understand the initial performance characteristics and confirm the safety profile of the NeuraGen 3D Nerve Guide Matrix.
What is the current status of trial NCT05343143?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2022-05-15. Estimated completion is 2024-05-13.
What interventions are being tested in trial NCT05343143?
The interventions under investigation include: NeuraGen 3D Nerve Guide Matrix (DEVICE).
Who is sponsoring clinical trial NCT05343143?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.